LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

Home・Aandelen Lijst・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Open

SectorGezondheidszorg

8.32 -0.48

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.2

Max

8.57

Belangrijke statistieken
By Trading Economics
Inkomsten	11M -20M
Verkoop	5.9M 40M
EPS	-0.19
Winstmarge	-49.569
Werknemers	184
EBITDA	16M -19M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+170.5% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	153M 901M
Vorige openingsprijs	8.8
Vorige sluitingsprijs	8.32

Nieuwssentiment

By Acuity

50%

167 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

6.26 / 7.47 Steun & Weerstand

Day One Biopharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 dec 2025, 23:21 UTC

Winsten

Acquisities, Fusies, Overnames

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dec 2025, 23:14 UTC

Acquisities, Fusies, Overnames

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dec 2025, 22:01 UTC

Belangrijke Marktbewegers

Costco Wholesale Reports Higher Monthly Sales

3 dec 2025, 21:38 UTC

Winsten

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dec 2025, 23:59 UTC

Marktinformatie

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dec 2025, 23:13 UTC

Marktinformatie

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dec 2025, 23:10 UTC

Winsten

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dec 2025, 23:08 UTC

Marktinformatie

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dec 2025, 23:06 UTC

Acquisities, Fusies, Overnames

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dec 2025, 22:59 UTC

Acquisities, Fusies, Overnames

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dec 2025, 22:45 UTC

Marktinformatie

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dec 2025, 22:20 UTC

Winsten

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dec 2025, 22:19 UTC

Winsten

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dec 2025, 22:17 UTC

Winsten

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dec 2025, 22:16 UTC

Winsten

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dec 2025, 22:15 UTC

Winsten

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dec 2025, 22:10 UTC

Acquisities, Fusies, Overnames

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dec 2025, 22:09 UTC

Acquisities, Fusies, Overnames

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

3 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

3 dec 2025, 21:49 UTC

Winsten

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:23 UTC

Winsten

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dec 2025, 21:19 UTC

Winsten

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:06 UTC

Winsten

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:04 UTC

Winsten

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dec 2025, 21:04 UTC

Winsten

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dec 2025, 21:03 UTC

Winsten

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer Vergelijking

Prijswijziging

Day One Biopharmaceuticals Inc Prognose

Koersdoel

By TipRanks

170.5% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 23.75 USD 170.5%

Hoogste 34 USD

Laagste 16 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Day One Biopharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Day One Biopharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

6.26 / 7.47Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

167 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.